This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
For patients in cohort 1: histologically proven lower grade glioma who are being followed with surveillance scans
For patients in cohort 2: histologically proven glioma who are scheduled for treatment due to suspected residual or recurrent tumor
Patients with a life expectancy > 12 weeks
Patients must have a Karnofsky performance status of >= 60
Subjects will be excluded from participating in this study if they are unable to comply with study and/or follow-up procedures
Susan Chang
Lead sponsor
University of California, San Francisco
Sponsor institution
GE Healthcare
Collaborator
Sigma-Aldrich
Collaborator
Phillips-Medisize
Collaborator
National Cancer Institute (NCI)
Collaborator